BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Khan S, Attar F, Bloukh SH, Sharifi M, Nabi F, Bai Q, Khan RH, Falahati M. A review on the interaction of nucleoside analogues with SARS-CoV-2 RNA dependent RNA polymerase. Int J Biol Macromol 2021;181:605-11. [PMID: 33766591 DOI: 10.1016/j.ijbiomac.2021.03.112] [Cited by in Crossref: 3] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Madariaga-Mazón A, Naveja JJ, Becerra A, Alberto Campillo-Balderas J, Hernández-Morales R, Jácome R, Lazcano A, Martinez-Mayorga K. Subtle structural differences of nucleotide analogs may impact SARS-CoV-2 RNA-dependent RNA polymerase and exoribonuclease activity. Comput Struct Biotechnol J 2022;20:5181-92. [PMID: 36097553 DOI: 10.1016/j.csbj.2022.08.056] [Reference Citation Analysis]
2 Munafò F, Donati E, Brindani N, Ottonello G, Armirotti A, De Vivo M. Quercetin and luteolin are single-digit micromolar inhibitors of the SARS-CoV-2 RNA-dependent RNA polymerase. Sci Rep 2022;12:10571. [PMID: 35732785 DOI: 10.1038/s41598-022-14664-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Chang J. 4'-Modified Nucleosides for Antiviral Drug Discovery: Achievements and Perspectives. Acc Chem Res 2022;55:565-78. [PMID: 35077644 DOI: 10.1021/acs.accounts.1c00697] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
4 Zakharova MY, Kuznetsova AA, Uvarova VI, Fomina AD, Kozlovskaya LI, Kaliberda EN, Kurbatskaia IN, Smirnov IV, Bulygin AA, Knorre VD, Fedorova OS, Varnek A, Osolodkin DI, Ishmukhametov AA, Egorov AM, Gabibov AG, Kuznetsov NA. Pre-Steady-State Kinetics of the SARS-CoV-2 Main Protease as a Powerful Tool for Antiviral Drug Discovery. Front Pharmacol 2021;12:773198. [PMID: 34938188 DOI: 10.3389/fphar.2021.773198] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
5 Niemeyer BF, Benam KH. Untapping host-targeting cross-protective efficacy of anticoagulants against SARS-CoV-2. Pharmacol Ther 2021;:108027. [PMID: 34718070 DOI: 10.1016/j.pharmthera.2021.108027] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
6 Ahmed S, Mahtarin R, Islam MS, Das S, Al Mamun A, Ahmed SS, Ali MA. Remdesivir analogs against SARS-CoV-2 RNA-dependent RNA polymerase. J Biomol Struct Dyn 2021;:1-14. [PMID: 34315339 DOI: 10.1080/07391102.2021.1955743] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
7 García-Trejo JJ, Ortega R, Zarco-Zavala M. Putative Repurposing of Lamivudine, a Nucleoside/Nucleotide Analogue and Antiretroviral to Improve the Outcome of Cancer and COVID-19 Patients. Front Oncol 2021;11:664794. [PMID: 34367956 DOI: 10.3389/fonc.2021.664794] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
8 Nabi F, Ahmad O, Khan YA, Nabi A, Md Amiruddin H, Abul Qais F, Masroor A, Hisamuddin M, Uversky VN, Khan RH. Computational studies on phylogeny and drug designing using molecular simulations for COVID-19. J Biomol Struct Dyn 2021;:1-10. [PMID: 34278954 DOI: 10.1080/07391102.2021.1947895] [Cited by in F6Publishing: 5] [Reference Citation Analysis]